Literature DB >> 21253779

Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis.

Akira Andoh1, Hirotsugu Imaeda, Tomoki Aomatsu, Osamu Inatomi, Shigeki Bamba, Masaya Sasaki, Yasuharu Saito, Tomoyuki Tsujikawa, Yoshihide Fujiyama.   

Abstract

BACKGROUND: Terminal restriction fragment length polymorphism (T-RFLP) analysis is a powerful tool to assess the diversity of a microbial community. In this study, we performed T-RFLP analysis of the fecal microbiota from patients with ulcerative colitis (UC) and those with Crohn's disease (CD).
METHODS: Thirty-one patients with UC, 31 patients with CD, and 30 healthy individuals were enrolled. The polymerase chain reaction (PCR) products obtained from the 16S rRNA genes of fecal samples were digested with BslI, and T-RF lengths were determined.
RESULTS: The fecal microbial communities were classified into 5 clusters. Twenty-eight of the 30 healthy individuals and 17 of the 18 patients with inactive UC were classified into clusters I, II, and III, but these clusters included a small number of patients with active UC and inactive/active CD. In contrast, 8 of the 13 patients with active UC and the majority of CD patients (12 of the 16 patients with inactive CD, and 11 of the 15 patients with active CD) were included in clusters IV and V. Based on the BslI-digested T-RFLP database, the bacteria showed a significant decrease in the Clostridium family in patients with active UC and inactive/active CD. In contrast, Bacteroides were significantly increased in CD patients. No significant differences were observed between patients with active UC and those with active CD.
CONCLUSION: The fecal microbial communities of IBD patients were different from those of healthy individuals. The gut microbiota of patients with inactive UC tended to be closer to that of healthy individuals, suggesting different roles for the fecal microbiota in the pathophysiology of UC and CD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253779     DOI: 10.1007/s00535-010-0368-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  47 in total

1.  Application of terminal RFLP analysis to characterize oral bacterial flora in saliva of healthy subjects and patients with periodontitis.

Authors:  Mitsuo Sakamoto; Yasuo Takeuchi; Makoto Umeda; Isao Ishikawa; Yoshimi Benno
Journal:  J Med Microbiol       Date:  2003-01       Impact factor: 2.472

Review 2.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

3.  Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis.

Authors:  Margarita Martinez-Medina; Xavier Aldeguer; Ferran Gonzalez-Huix; Doroteo Acero; L Jesús Garcia-Gil
Journal:  Inflamm Bowel Dis       Date:  2006-12       Impact factor: 5.325

4.  Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis.

Authors:  Uri Gophna; Katrin Sommerfeld; Sharon Gophna; W Ford Doolittle; Sander J O Veldhuyzen van Zanten
Journal:  J Clin Microbiol       Date:  2006-09-20       Impact factor: 5.948

Review 5.  Advances in the use of terminal restriction fragment length polymorphism (T-RFLP) analysis of 16S rRNA genes to characterize microbial communities.

Authors:  Ursel M E Schütte; Zaid Abdo; Stephen J Bent; Conrad Shyu; Christopher J Williams; Jacob D Pierson; Larry J Forney
Journal:  Appl Microbiol Biotechnol       Date:  2008-07-22       Impact factor: 4.813

6.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

7.  Rapid and noninvasive metabonomic characterization of inflammatory bowel disease.

Authors:  Julian R Marchesi; Elaine Holmes; Fatima Khan; Sunil Kochhar; Pauline Scanlan; Fergus Shanahan; Ian D Wilson; Yulan Wang
Journal:  J Proteome Res       Date:  2007-02       Impact factor: 4.466

8.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

Review 9.  Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease.

Authors:  Akira Andoh; Yoshimi Benno; Osamu Kanauchi; Yoshihide Fujiyama
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis.

Authors:  Akira Andoh; Shinji Sakata; Yuhsuke Koizumi; Keiichi Mitsuyama; Yoshihide Fujiyama; Yoshimi Benno
Journal:  Inflamm Bowel Dis       Date:  2007-08       Impact factor: 5.325

View more
  65 in total

Review 1.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

2.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease.

Authors:  Akira Andoh; Hiroyuki Kuzuoka; Tomoyuki Tsujikawa; Shiro Nakamura; Fumihito Hirai; Yasuo Suzuki; Toshiyuki Matsui; Yoshihide Fujiyama; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2012-05-11       Impact factor: 7.527

3.  Innate immunity and inflammatory bowel disease: a review of clinical evidence and future application.

Authors:  Kyoko Katakura; Hiroshi Watanabe; Hiromasa Ohira
Journal:  Clin J Gastroenterol       Date:  2013-11-22

4.  Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis.

Authors:  Atsushi Nishida; Hirotsugu Imaeda; Masashi Ohno; Osamu Inatomi; Shigeki Bamba; Mitsushige Sugimoto; Akira Andoh
Journal:  J Gastroenterol       Date:  2016-10-11       Impact factor: 7.527

5.  The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis.

Authors:  Asuka Yasueda; Tsunekazu Mizushima; Riichiro Nezu; Ryoko Sumi; Mamoru Tanaka; Junichi Nishimura; Yasuyuki Kai; Masaki Hirota; Hideki Osawa; Kiyokazu Nakajima; Masaki Mori; Toshinori Ito
Journal:  Surg Today       Date:  2015-10-29       Impact factor: 2.549

Review 6.  Inflammatory bowel disease: pathogenesis.

Authors:  Yi-Zhen Zhang; Yong-Yu Li
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

7.  Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model.

Authors:  Qin Qi; Ya-Nan Liu; Xiao-Ming Jin; Lin-Shuang Zhang; Cun Wang; Chun-Hui Bao; Hui-Rong Liu; Huan-Gan Wu; Xiao-Mei Wang
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

8.  Polyphenol-rich sorghum brans alter colon microbiota and impact species diversity and species richness after multiple bouts of dextran sodium sulfate-induced colitis.

Authors:  Lauren E Ritchie; Joseph M Sturino; Raymond J Carroll; Lloyd W Rooney; M Andrea Azcarate-Peril; Nancy D Turner
Journal:  FEMS Microbiol Ecol       Date:  2015-01-14       Impact factor: 4.194

Review 9.  Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India.

Authors:  Saurabh Kedia; Ritika Rampal; Jaishree Paul; Vineet Ahuja
Journal:  J Gastroenterol       Date:  2016-03-19       Impact factor: 7.527

10.  Epithelial expression of interleukin-37b in inflammatory bowel disease.

Authors:  H Imaeda; K Takahashi; T Fujimoto; E Kasumi; H Ban; S Bamba; H Sonoda; T Shimizu; Y Fujiyama; A Andoh
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.